BRONCHODILATOR RESPONSE AT LOW LUNG-VOLUMES PREDICTS BRONCHIOLITIS OBLITERANS IN LUNG-TRANSPLANT RECIPIENTS

Citation
N. Rajagopalan et al., BRONCHODILATOR RESPONSE AT LOW LUNG-VOLUMES PREDICTS BRONCHIOLITIS OBLITERANS IN LUNG-TRANSPLANT RECIPIENTS, Chest, 109(2), 1996, pp. 405-407
Citations number
14
Categorie Soggetti
Respiratory System
Journal title
ChestACNP
ISSN journal
00123692
Volume
109
Issue
2
Year of publication
1996
Pages
405 - 407
Database
ISI
SICI code
0012-3692(1996)109:2<405:BRALLP>2.0.ZU;2-W
Abstract
Background: Bronchiolitis obliterans syndrome (BOS) is the major obsta cle to long-term lung allograft viability. The diagnosis often occurs after significant organ dysfunction is present, and BOS is often unres ponsive to standard immunosuppressive agents. We have observed broncho dilator responses (BRs) at low lung volumes in many of our patients wh o have developed BOS. We therefore assessed whether BR could predict t he development of BOS. Methods: We conducted a retrospective review of the clinical and pulmonary function laboratory records of 146 patient s who underwent transplantation between March 1983 and November 1993. BR was defined as 25% or more increase in forced expiratory flow at 50 % of vital capacity or 30% or more increase in forced expiratory flow at 75% of vital capacity. BOS was defined according to recently publis hed FEV(1) criteria. Bronchiolitis obliterans was defined histological ly according to criteria of the Lung Rejection Study Group. Results: O f the total population, 52 were excluded because of death or insuffici ent information. BRs of the small ail-ways were seen in 31 patients (3 3%), 25 of whom developed BOS (83%). Approximately half of those with BR who developed BOS had evidence of acute rejection in the month prio r to the onset of BR. Two thirds (four of six) of patients with BR not developing BOS had acute rejection in the previous month. The sensiti vity of BR in predicting BOS was 51% with a specificity df 87%. The po sitive predictive value was 81%. Conclusions: BR appears to be useful as an early marker of BOS. The development of BR in selected patients should lead to closer monitoring and possibly a trial of augmented imm unosuppression to arrest the establishment of BOS.